Full Press Release Details
Marker Therapeutics to Report Updated
Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
Data selected for oral presentation during
a plenary session at AACR's Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of
Adoptive Therapy Conference
Company to host investor event and webcast
- June 20, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company
specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies
and solid tumor indications, today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by
Baylor College of Medicine were selected for oral presentation during a plenary session at the upcoming American Association for
Cancer Research's (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive
Therapy conference. The data-which will also be presented in a poster session-will be reviewed by Brandon G. Smaglo,
M.D., FACP, Assistant Professor, Medical Director of Hematology/Oncology at the Baylor College of Medicine, Houston, Texas.
Title: "Targeting pancreatic
cancer using nonengineered, multiantigen-specific T cells (TACTOPS)"
Session #1): 8:00 a.m. - 10:00 a.m. PST
Hyatt Regency, San Francisco, CA
Title: "Targeting pancreatic
cancer using nonengineered, multiantigen-specific T cells (TACTOPS)"
Session A): 12:30 p.m. - 2:30 p.m. PST
Hyatt Regency, San Francisco, CA
For those unable to attend the presentations at AACR, Marker will host a live investor event following the conference on Monday,
July 22nd at 1:30 p.m. PST in San Francisco featuring Dr. Brandon Smaglo, as well as Marker senior management. A live webcast of
the investor presentation will be available in the investors section of the Company's website at https://www.markertherapeutics.com/ and
will be available for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies
for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on
the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets)
and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following
infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because
Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less expensive
to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product
profile, as compared to current gene-modified CAR-T and TCR-based therapies.
advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including
the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer,
currently in Phase 2 clinical trials.
information, please call toll free at (904) 862-6490 or visit: https://www.markertherapeutics.com/
press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance
or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs; the effectiveness
of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases;
and, the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking
statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth
in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The
Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or
otherwise, after the date of this press release.